Insider Transactions in Q1 2025 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 13
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,599
-2.65%
|
$44,772
$28.7 P/Share
|
|
Jan 13
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,288
-0.2%
|
$64,064
$28.7 P/Share
|
|
Jan 13
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
783
-2.05%
|
$21,924
$28.7 P/Share
|
|
Jan 08
2025
|
Keli Walbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,090
+50.0%
|
-
|
|
Jan 06
2025
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,816
-4.82%
|
$92,928
$33.81 P/Share
|
|
Jan 01
2025
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+26.14%
|
-
|
|
Jan 01
2025
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+1.64%
|
-
|
|
Jan 01
2025
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+3.81%
|
-
|
|
Jan 01
2025
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+21.63%
|
-
|
|
Jan 01
2025
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+26.14%
|
-
|